MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Taxorest Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Taxorest (bronchial Cytomax A-19) is the bronchopulmonary peptide bioregulator in Vladimir Khavinson's Cytomax line, a complex of short peptides extracted from animal bronchial mucosa and sold in 10 mg oral capsules. Like other Khavinson ultrashort peptides, it is proposed to enter cells, bind specific DNA promoter regions, and regulate tissue-specific gene expression and protein synthesis in bronchial epithelium, supporting ciliated-cell renewal, secretory IgA, and a normalized cytokine balance (PMID 25015171, 26468022). Its synthetic counterpart, the tetrapeptide Bronchogen (Ala-Glu-Asp-Leu), is the molecule used in most controlled laboratory studies of the class. In practice it is taken at 20 mg/day before meals for 10-30 day courses repeated every 3-6 months, primarily in Russian and Eastern-European respiratory and longevity protocols. Independent clinical evidence is limited and no randomized trials exist; Taxorest is a Russian-registered dietary supplement, not an FDA- or EMA-approved drug, and the reconstitution figures here are an educational reference only.
Reconstitute: Add 2 mL bacteriostatic water → 10 mg/mL concentration.
Typical dose: 20 mg/day orally (2 caps); 10-40 mg/day range
Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 0.1 mg (100 mcg) on a U-100 insulin syringe.
Storage: Capsules: store at room temperature (15-25°C), dry and away from light. Educational reconstituted reference vial: refrigerate at 2-8°C and avoid repeated freeze-thaw.
Half-life: Not formally characterized. Free short peptides clear from plasma within minutes to a few hours; bioregulator courses are pulsed (10-30 days) and repeated every 3-6 months.
Route: Oral capsules (10 mg) or sublingual drops, taken before meals. The subcutaneous reconstitution figures on this page are an educational reference only.
Status: Not FDA- or EMA-approved. Registered in Russia as a dietary supplement (biologically active food additive); research/educational use elsewhere.
About Taxorest
Taxorest is the bronchopulmonary member of the Khavinson Cytomax family, a natural peptide complex (catalog code A-19) isolated from bronchial tissue and sold clinically as a 10 mg oral capsule rather than an injectable [1][4]. Clinically it is taken by mouth, so the subcutaneous figures below are an educational reconstitution reference only, included so the Taxorest dosage can be compared on the same footing as the injectable peptides catalogued on this site.
The real-world protocol is simple: 1-2 capsules once or twice daily before meals, giving a typical 20 mg/day dose across a 10- to 30-day course that is repeated every 3-6 months [2]. The educational reconstitution model below converts a 20 mg vial into measurable insulin-syringe units, scaled to the mcg-level research dosing used for the synthetic analog Bronchogen so the protocol can be visualized [3].
Frequency: Inject once daily subcutaneously (educational reference only); clinically Taxorest is taken as 1-2 oral capsules per day before meals.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2.0 mL of bacteriostatic water into a sterile syringe.
Inject the water slowly down the inside wall of the 20 mg Taxorest vial; do not spray directly onto the lyophilized peptide.
Swirl or roll the vial gently until fully dissolved; never shake, which can shear the peptide and cause foaming.
Swab the stopper, then withdraw the prescribed dose (for example, 1,000 mcg = 10 units on a U-100 insulin syringe).
Inject subcutaneously into the abdomen; do not aspirate, inject slowly, and store the reconstituted vial refrigerated between doses.
Interactive Taxorest Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 2mL water yields 10.00 mg/mL. To evaluate a 250mcg dose, pull to 2.5 units (3 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Initiation (Week 1) | 500 mcg | 5 units (0.05 mL) |
| Standard course (Weeks 2-4) | 1000 mcg (1 mg) | 10 units (0.10 mL) |
| Extended course (Weeks 5+) | 1500 mcg (1.5 mg) | 15 units (0.15 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Taxorest, 20 mg each):
- check8 weeks ≈ 4 vials (~67 mg total)
- check12 weeks ≈ 6 vials (~109 mg total)
- check16 weeks ≈ 8 vials (~151 mg total)
Insulin Syringes (U-100):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use 2 mL per vial for reconstitution.
- check8 weeks (4 vials): 8 mL → 1 × 10 mL bottle
- check12 weeks (6 vials): 12 mL → 2 × 10 mL bottles
- check16 weeks (8 vials): 16 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100-count boxes
- check12 weeks: 168 swabs → recommend 2 × 100-count boxes
- check16 weeks: 224 swabs → recommend 3 × 100-count boxes
Mechanism of Action (MOA)
Taxorest is a natural peptide bioregulator, the bronchopulmonary entry (catalog code A-19) in Vladimir Khavinson's "Cytomax" line developed at the St. Petersburg Institute of Bioregulation and Gerontology. Unlike a single synthetic peptide, each 10 mg capsule contains a concentrated complex of low-molecular-weight peptide fractions extracted from the bronchial mucosa of young animals; these fragments are selected to be tissue-specific for the cells of the bronchi and lungs [1][4]. Its fully synthetic counterpart is the tetrapeptide Bronchogen (Ala-Glu-Asp-Leu, also reported as Ala-Asp-Glu-Leu), which is the molecule used in most of the controlled laboratory work on the bronchopulmonary peptide class [1][3]. The central hypothesis of the Khavinson program is that ultrashort peptides act as epigenetic regulators. Because of their small size (roughly 300-700 Da), they are proposed to cross the cell and nuclear membranes, bind specific promoter regions of double-stranded DNA, and thereby switch on or modulate transcription of genes that govern differentiation and maintenance of the target tissue [4][5]. Biophysical support for direct DNA interaction comes from work showing that the bronchial tetrapeptide raises the melting temperature of DNA, consistent with sequence-specific binding [3]. In bronchial epithelial cell and tissue models, peptide exposure has been reported to upregulate genes and proteins associated with ciliated-cell differentiation, mucosal repair, and local immunity [1]. Downstream, the proposed effect of Taxorest is restoration of bronchial epithelial structure and function. In a rat model of obstructive lung pathology, peptide therapy reduced goblet-cell hyperplasia, squamous metaplasia, and lymphocytic infiltration, restored ciliated cells, increased secretory IgA as a marker of local immunity, and normalized the pro-inflammatory cytokine profile [2]. These changes are the basis for its use in Russian and Eastern-European practice for chronic bronchitis, COPD, bronchial asthma, post-pneumonia recovery, and so-called "smoker's cough" [2]. Pharmacokinetics for the natural complex have not been formally characterized in peer-reviewed Western literature. The clinical route is oral: 1-2 capsules taken before meals so the peptides are absorbed in the small intestine. Free short peptides clear from plasma within minutes to a few hours, so Taxorest has no meaningful steady-state half-life in the conventional sense; instead the bioregulator model assumes a durable regulatory effect that justifies short pulsed courses (10-30 days) repeated every 3-6 months rather than continuous dosing [6][7]. The subcutaneous reconstitution figures on this page are an educational reference only, scaled to mcg-level injection doses typical of the synthetic analog so the protocol can be visualized on an insulin syringe. Critically, evidence outside the Khavinson group is limited, no independent randomized controlled trials exist, and the compound has not been evaluated by the FDA or EMA [4][6].
Clinical Trial Efficacy Highlights
- starIn bronchial epithelial cell and tissue models, Khavinson and colleagues reported that the bronchopulmonary tetrapeptide regulates gene expression and protein synthesis associated with epithelial differentiation and mucosal maintenance, providing the mechanistic basis cited for Taxorest's bronchial activity [1].
- starIn a rat model of chronic obstructive lung pathology, peptide therapy reduced goblet-cell hyperplasia, squamous metaplasia and lymphocytic infiltration, restored ciliated cells, raised secretory IgA, and normalized the pro-inflammatory cytokine profile relative to untreated animals [2].
- starBiophysical work showed that the synthetic bronchial peptide Bronchogen (Ala-Asp-Glu-Leu) increased the thermal stability (melting temperature) of DNA, a result interpreted as support for the proposed sequence-specific DNA-binding mechanism of the Khavinson short-peptide class [3].
- starA 2021 systematic review of peptide regulation of gene expression catalogued how ultrashort Khavinson peptides modulate tissue-specific transcription across multiple organ systems, situating the bronchopulmonary peptide within a broader, internally consistent research program [4].
- starReviews of peptide regulation of cell differentiation describe short peptides influencing stem and progenitor cell commitment in target tissues, the framework used to explain the epithelial regeneration claimed for Taxorest [5].
- starKhavinson and Anisimov's summary of 35 years of peptide-bioregulator research reports geroprotective and lifespan effects in rodent models dosed cyclically over years; these findings originate largely from the founding group and have not been broadly replicated by independent laboratories [6][7].
- starNo randomized controlled clinical trials of Taxorest in human respiratory disease have been published in peer-reviewed English-language journals, and the natural peptide complex has not been evaluated by the FDA or EMA; clinical use remains investigational and is based on Russian-language and manufacturer sources [4].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningManufacturer and Russian-language sources describe Taxorest as well tolerated, with the principal documented contraindications being individual hypersensitivity to the peptide complex, pregnancy, and breastfeeding.
- warningAs an oral capsule, the most plausible adverse effects are mild gastrointestinal upset (nausea, fullness) and, rarely, allergic or hypersensitivity reactions to the peptide fractions or capsule excipients.
- warningBecause the peptides are extracted from animal (bovine) bronchial tissue, there is a theoretical, unquantified concern about animal-sourced biologic material; product quality and purity vary by supplier and are not subject to pharmaceutical-grade regulatory oversight.
- warningIndependent human safety, toxicology, and long-term data are essentially absent, and the proposed broad gene-expression modulation has not been characterized for off-target effects on tissues other than the bronchopulmonary system.
- warningUse in pregnancy, lactation, children, and in patients with active or treated malignancy has not been studied and is generally discouraged.
- warningDrug-interaction data are lacking; combining Taxorest with prescription respiratory therapy (inhaled corticosteroids, bronchodilators) has not been formally evaluated and should not replace guideline-based care.
- warningThe subcutaneous reconstitution reference on this page is educational only; if research-grade peptide is ever injected, non-sterile technique and variable purity create real risks of injection-site infection and reaction.
- warningTaxorest is not FDA- or EMA-approved; it is sold as a dietary supplement (biologically active food additive) in Russia and should be regarded as a research/educational compound elsewhere.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Taxorest dosage?expand_more
The standard Taxorest dosage is 20 mg per day, taken as two 10 mg capsules before meals, with a practical range of 10-40 mg/day (1-4 capsules). A typical course runs 10-30 days and is repeated every 3-6 months. A sublingual liquid form is dosed at roughly 10 drops twice daily. There is no validated injectable dose; the subcutaneous figures on this page are an educational reference only.
How is Taxorest taken, and can it be reconstituted for injection?expand_more
Clinically, Taxorest is taken orally as capsules (or sublingual drops) before meals, because it is a natural peptide complex, not an injectable drug. The reconstitution steps here are an educational model that dissolves a 20 mg vial in 2 mL of bacteriostatic water so mcg-scale doses can be drawn on a U-100 insulin syringe; this mirrors how the site presents other oral and topical compounds and is not a manufacturer-endorsed route.
What is the half life of Taxorest?expand_more
No formal pharmacokinetic half-life has been published for Taxorest. Free short peptides are typically cleared from plasma within minutes to a few hours. The Khavinson bioregulator model assumes the regulatory effect outlasts plasma presence, which is why courses are pulsed (10-30 days) and repeated every few months rather than dosed continuously.
Can Taxorest be stacked with other peptide bioregulators?expand_more
In Khavinson-style protocols Taxorest is frequently combined with other tissue-specific bioregulators such as Vladonix (thymus), Ventfort (vascular), or the synthetic analog Bronchogen, and it is sometimes sold in respiratory blends. These combinations are based on practitioner convention rather than controlled trials, and stacking with prescription respiratory medication has not been formally studied.
Is Taxorest FDA approved?expand_more
No. Taxorest is not approved by the FDA or EMA for any indication. It is registered in Russia and several CIS countries as a dietary supplement (biologically active food additive), not as a drug. Outside those markets it should be regarded as a research/educational compound, and this page is not medical advice.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Taxorest, plus the universal dosing calculator.
Academic References & Study Citations
Khavinson VKh, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014;192(5):781-791. doi:10.1007/s00408-014-9620-7. View Scientific Paper →
Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, Surkova EA, Platonova IS, Titova ON. Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology. Bull Exp Biol Med. 2015;159(5):685-688. View Scientific Paper →
Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, Khachidze DG, Lomidze EM, Jokhadze TA, Lezhava TA. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bull Exp Biol Med. 2011;150(3):375-377. View Scientific Paper →
Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. doi:10.3390/molecules26227053. View Scientific Paper →
Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide Regulation of Cell Differentiation. Stem Cell Rev Rep. 2020;16(1):118-125. doi:10.1007/s12015-019-09938-8. View Scientific Paper →
Khavinson VKh, Anisimov VN. Peptide regulation of aging: 35-year research experience. Bull Exp Biol Med. 2009;148(1):94-98. View Scientific Paper →
Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. View Scientific Paper →